6 results about "Doxorubicinone" patented technology

This invention belongs to the field of biomedical technology, specifically disclosing a nanomicelle FluDox-MIC, its preparation method, and its uses. This nanomicelle is formed by the self-assembly of flumatinib and doxorubicin co-loaded in mPEG-DSPE, exhibiting pH-responsive release properties. Upon entering the tumor microenvironment, it releases the drug. The released flumatinib induces the degradation of the poliovirus receptor (PVR / CD155), relieving its inhibitory signal on NK cells and reactivating innate immune surveillance. Simultaneously, low-dose doxorubicin induces significant immunogenic cell death (ICD), initiating and amplifying tumor-specific T cell-mediated adaptive immunity. Through the synergistic activation of innate and adaptive immunity, the nanomicelle of this invention can effectively inhibit melanoma growth and overcome immunotherapy resistance, showing promising clinical application prospects.

This invention discloses a helical elongated cavity multi-walled mesoporous silica microparticle, its preparation method, and its application, relating to the field of materials preparation technology. The technical solution involves dissolving dimethylbis(tetradecyl)ammonium bromide in water, adding an alkaline solution, stirring thoroughly to obtain a mixed solution, then adding a silicate ester and stirring to react; the product is purified by centrifugation, washed with water, and ultrasonically treated in an acidic ethanol solution to obtain helical elongated cavity multi-walled mesoporous silica microparticles. The elongated cavities of this invention extend helically in the same plane, and the cavity walls have a concentric tubular multilayer structure, thus possessing a "multi-walled" structure; using doxorubicin as a model small molecule drug, these microparticles exhibit efficient loading and sustained-release capabilities.

The application relates to application of TNFRSF13B in preparation of a medicine for treating relapsed refractory diffuse large B-cell lymphoma. Research finds that TNFRSF13B has specific expression in relapsed refractory diffuse large B-cell lymphoma and is closely related to the survival of DLBCL patients, in-vitro cell experiments and in-vivo animal experiments verify that TNFRSF13B plays an important role in maintaining the clonal formation ability, continuous passage proliferation and doxorubicin resistance phenotype, and the blocking can significantly inhibit the tumor initiation ability, which indicates potential application value of TNFRSF13B in diagnosis, prognosis evaluation and treatment of relapsed refractory diffuse large B-cell lymphoma.

Treatment combinations are provided for FOLR1-binding immunoconjugates (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), platinum-based agents, and / or doxorubicin. Methods for administering said combinations to treat cancers, such as ovarian cancer, with increased clinical efficacy and / or reduced toxicity are also provided.

This invention belongs to the field of biomedical technology and discloses a novel TNNT2 gene mutation c.311G>A associated with dilated cardiomyopathy. Through pedigree genetic analysis and in vitro functional validation, it was confirmed that this mutation leads to increased sensitivity of cardiomyocytes to doxorubicin and mitochondrial network fragmentation, thus exhibiting pathogenicity. Based on this, this invention provides specific detection primer pairs and kits for rapid genetic diagnosis and risk assessment of dilated cardiomyopathy.